{
  "id": "map_1821",
  "title": "DiagnÃ³stico y tratamiento de la\\Ntrombosis venosa cerebral",
  "specialty": "Continuum",
  "tag": "â­ Estudio Pivotal",
  "node_count": 372,
  "root": {
    "text": "DiagnÃ³stico y tratamiento de la\\Ntrombosis venosa cerebral",
    "children": [
      {
        "text": "â¤ DefiniciÃ³n",
        "children": [
          {
            "text": "â®• Representa <1% de todos los ACV",
            "children": []
          },
          {
            "text": "â®• Afecta jÃ³venes (predominio femenino)",
            "children": []
          },
          {
            "text": "â®• Inicio no apoplÃ©ctico, espectro clÃ­nico amplio",
            "children": []
          },
          {
            "text": "â®• DesafÃ­o diagnÃ³stico sin conocimiento de epidemiologÃ­a, clÃ­nica y neuroimagen",
            "children": []
          }
        ]
      },
      {
        "text": "ANATOMÃA Y FISIOPATOLOGÃA",
        "children": [
          {
            "text": "â¤ UbicaciÃ³n de\\Nlos trombos",
            "children": [
              {
                "text": "â®• Senos venosos\\Ndurales",
                "children": [
                  {
                    "text": "âœ”ï¸ Seno sagital superior (mÃ¡s frecuente)",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Senos transversos â†’ Sigmoideos â†’ Vena yugular interna",
                    "children": []
                  }
                ]
              },
              {
                "text": "â®• Sistema venoso\\Nprofundo",
                "children": [
                  {
                    "text": "âœ”ï¸ Seno recto, Vena de Galeno, Seno sagital inferior",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Venas cerebrales internas (drenan tÃ¡lamo y ganglios basales)",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Venas de Rosenthal",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "â¤ Mecanismo",
            "children": [
              {
                "text": "â®• Trombosis inicia en\\Nsenos venosos durales",
                "children": [
                  {
                    "text": "âœ”ï¸ PropagaciÃ³n a venas corticales",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Infarto venoso y/o hipertensiÃ³n intracraneal (HIC)",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "EPIDEMIOLOGÃA",
        "children": [
          {
            "text": "â¤ Incidencia\\Nen adultos",
            "children": [
              {
                "text": "â®• 1.32-2 por 100,000 habitantes/aÃ±o",
                "children": []
              },
              {
                "text": "â®• 0.66% de admisiones por ACV (EE.UU., 2005-2016)",
                "children": []
              },
              {
                "text": "â®• â†‘ 70% en incidencia de CVT (2005-2016)",
                "children": []
              },
              {
                "text": "â®• Mayor incremento en hombres y mujeres mayores",
                "children": []
              }
            ]
          },
          {
            "text": "â¤ Predominio en\\Nmujeres jÃ³venes",
            "children": [
              {
                "text": "â®• CVT en 18-44 aÃ±os: 3x mÃ¡s frecuente en mujeres",
                "children": []
              },
              {
                "text": "â®• Incidencia estable en EE. UU.: 2.9-3.3/100,000",
                "children": []
              },
              {
                "text": "â®• Factores\\NespecÃ­ficos de sexo:",
                "children": [
                  {
                    "text": "âœ”ï¸ Anticonceptivos orales",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Embarazo",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Puerperio",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "â¤ Factores raciales\\N(datos limitados)",
            "children": [
              {
                "text": "â®• Mayor incidencia en personas negras",
                "children": []
              },
              {
                "text": "â®• RelaciÃ³n con tromboembolismo venoso y trombosis venosa profunda",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "CONDICIONES\\NASOCIADAS A CVT",
        "children": [
          {
            "text": "ğŸ“Œ 80% de pacientes con CVT tienen â‰¥1 condiciÃ³n asociada",
            "children": []
          },
          {
            "text": "ğŸ“Œ 50% tienen â‰¥2 condiciones",
            "children": []
          },
          {
            "text": "â¤ Factores predisponentes\\N(genÃ©ticos/protrombÃ³ticos)",
            "children": [
              {
                "text": "âœ”ï¸ Mutaciones: Factor V Leiden, Protrombina G20210A",
                "children": []
              },
              {
                "text": "âœ”ï¸ DÃ©ficits de proteÃ­na C, S, antitrombina",
                "children": []
              },
              {
                "text": "âœ”ï¸ SÃ­ndrome antifosfolÃ­pidos",
                "children": []
              },
              {
                "text": "âœ”ï¸ CÃ¡ncer",
                "children": []
              }
            ]
          },
          {
            "text": "â¤ Factores\\Nprecipitantes",
            "children": [
              {
                "text": "âœ”ï¸ Anticonceptivos orales",
                "children": []
              },
              {
                "text": "âœ”ï¸ Infecciones (meningitis, sinusitis, COVID-19)",
                "children": []
              },
              {
                "text": "âœ”ï¸ CirugÃ­a reciente, trauma craneal",
                "children": []
              },
              {
                "text": "âœ”ï¸ Estados inflamatorios crÃ³nicos (LES, enfermedad inflamatoria intestinal)",
                "children": []
              },
              {
                "text": "âœ”ï¸ DeshidrataciÃ³n",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ Buscar mÃºltiples factores en cada paciente",
            "children": []
          }
        ]
      },
      {
        "text": "COVID-19 Y CVT",
        "children": [
          {
            "text": "ğŸ“Œ CVT descrita como complicaciÃ³n de COVID-19",
            "children": []
          },
          {
            "text": "â¤ InfecciÃ³n por\\NSARS-CoV-2",
            "children": [
              {
                "text": "â®• Incidencia 0.08% en pacientes hospitalizados",
                "children": []
              },
              {
                "text": "â®• Trombosis ocurre 1-8 semanas post-COVID",
                "children": []
              },
              {
                "text": "â®• Alta mortalidad (~50%)",
                "children": []
              }
            ]
          },
          {
            "text": "â¤ Vacunas COVID-19\\N(Adenovirus: ChAdOx1, Ad26. COV2.S)",
            "children": [
              {
                "text": "â®• CVT con trombocitopenia (VITT)",
                "children": []
              },
              {
                "text": "â®• Aparece 5-24 dÃ­as postvacunaciÃ³n",
                "children": []
              },
              {
                "text": "â®• Mortalidad inicial 50%, ahora ~22% (mejor manejo)",
                "children": []
              },
              {
                "text": "â®• DiagnÃ³stico: Anti-PF4 ELISA",
                "children": []
              },
              {
                "text": "â®• Evitar heparina â†’ AnticoagulaciÃ³n alternativa recomendada",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ Riesgo de CVT postvacuna COVID-19 es mucho menor que por infecciÃ³n por COVID-19",
            "children": []
          }
        ]
      },
      {
        "text": "FACTORES DE\\NRIESGO PARA CVT",
        "children": [
          {
            "text": "1ï¸âƒ£ FACTORES\\NPREDISPONENTES",
            "children": [
              {
                "text": "ğŸ“Œ Condiciones que aumentan la susceptibilidad a CVT",
                "children": []
              },
              {
                "text": "âœ”ï¸ Consumo de alcohol",
                "children": []
              },
              {
                "text": "âœ”ï¸ Hipercolesterolemia",
                "children": []
              },
              {
                "text": "âœ”ï¸ Hiperhomocisteinemia",
                "children": []
              },
              {
                "text": "âœ”ï¸ SÃ­ndrome antifosfolÃ­pido (presencia de anticuerpos antifosfolÃ­pidos)",
                "children": []
              },
              {
                "text": "âœ”ï¸ Enfermedades autoinmunes",
                "children": []
              },
              {
                "text": "âœ”ï¸ Anemia",
                "children": []
              },
              {
                "text": "âœ”ï¸ CÃ¡ncer (mayor riesgo en el primer aÃ±o del diagnÃ³stico y en hematolÃ³gicas)",
                "children": []
              },
              {
                "text": "âœ”ï¸ Embarazo y puerperio",
                "children": [
                  {
                    "text": "â®• Riesgo 4 veces mayor en el primer trimestre postparto (mÃ¡s alto en las primeras 6 semanas)",
                    "children": []
                  }
                ]
              },
              {
                "text": "âœ”ï¸ Polimorfismos genÃ©ticos",
                "children": [
                  {
                    "text": "â®• Factor V Leiden (G1691A)",
                    "children": []
                  },
                  {
                    "text": "â®• MutaciÃ³n MTHFR (C677T)",
                    "children": []
                  },
                  {
                    "text": "â®• MutaciÃ³n en la protrombina (G20210A)",
                    "children": []
                  }
                ]
              },
              {
                "text": "âœ”ï¸ Deficiencias de\\Nanticoagulantes naturales",
                "children": [
                  {
                    "text": "â®• ProteÃ­na C",
                    "children": []
                  },
                  {
                    "text": "â®• ProteÃ­na S",
                    "children": []
                  },
                  {
                    "text": "â®• Antitrombina III",
                    "children": []
                  }
                ]
              },
              {
                "text": "âœ”ï¸ Obesidad en mujeres (especialmente con anticonceptivos orales)",
                "children": []
              },
              {
                "text": "âœ”ï¸ Niveles elevados de Factor VIII",
                "children": []
              },
              {
                "text": "âœ”ï¸ Enfermedad de BehÃ§et",
                "children": []
              }
            ]
          },
          {
            "text": "2ï¸âƒ£ FACTORES\\NPRECIPITANTES",
            "children": [
              {
                "text": "ğŸ“Œ Eventos que desencadenan la trombosis en individuos predispuestos",
                "children": []
              },
              {
                "text": "âœ”ï¸ Uso de glucocorticoides",
                "children": []
              },
              {
                "text": "âœ”ï¸ Trauma",
                "children": []
              },
              {
                "text": "âœ”ï¸ InfecciÃ³n (SNC o cara)",
                "children": []
              },
              {
                "text": "âœ”ï¸ Procedimientos quirÃºrgicos",
                "children": []
              },
              {
                "text": "âœ”ï¸ Anticonceptivos hormonales combinados",
                "children": []
              },
              {
                "text": "âœ”ï¸ PÃºrpura trombÃ³tica trombocitopÃ©nica inducida por vacunas",
                "children": []
              },
              {
                "text": "âœ”ï¸ Tratamientos especÃ­ficos",
                "children": [
                  {
                    "text": "â®• L-asparaginasa",
                    "children": []
                  },
                  {
                    "text": "â®• Ãcido all-trans retinoico (ATRA) (en leucemia promielocÃ­tica aguda)",
                    "children": []
                  }
                ]
              },
              {
                "text": "âœ”ï¸ PunciÃ³n lumbar",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ IMPORTANTE",
            "children": [
              {
                "text": "âœ”ï¸ CVT es multifactorial â†’ frecuente combinaciÃ³n de factores predisponentes y precipitantes",
                "children": []
              },
              {
                "text": "âœ”ï¸ Alto riesgo en embarazo/puerperio y anticonceptivos orales",
                "children": []
              },
              {
                "text": "âœ”ï¸ Tratar factores modificables (anticonceptivos, obesidad, alcohol, hiperlipidemia)",
                "children": []
              },
              {
                "text": "âœ”ï¸ EvaluaciÃ³n genÃ©tica en pacientes con historia familiar de trombosis",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "IMAGEN Y\\NDIAGNÃ“STICO",
        "children": [
          {
            "text": "âœ”ï¸ TAC simple",
            "children": [
              {
                "text": "âœ”ï¸ Signo del cordÃ³n hiperdenso (trombo en seno venoso)",
                "children": []
              },
              {
                "text": "âœ”ï¸ Hemorragia intraparenquimatosa con extensiÃ³n subaracnoidea",
                "children": []
              }
            ]
          },
          {
            "text": "âœ”ï¸ TAC venografÃ­a",
            "children": [
              {
                "text": "âœ”ï¸ ConfirmaciÃ³n de trombosis venosa",
                "children": []
              }
            ]
          },
          {
            "text": "âœ”ï¸ RM con venografÃ­a (MRV)",
            "children": [
              {
                "text": "âœ”ï¸ Trombosis en senos venosos y venas corticales",
                "children": []
              }
            ]
          },
          {
            "text": "âœ”ï¸ AngiografÃ­a cerebral (casos atÃ­picos)",
            "children": []
          }
        ]
      },
      {
        "text": "MANEJO DE CVT",
        "children": [
          {
            "text": "1ï¸âƒ£ AnticoagulaciÃ³n",
            "children": [
              {
                "text": "ğŸ“Œ Tratamiento principal, incluso en presencia de hemorragia",
                "children": []
              },
              {
                "text": "âœ”ï¸ HBPM (preferida) o warfarina (INR 2-3)",
                "children": []
              },
              {
                "text": "âœ”ï¸ Evitar heparina en VITT â†’ Alternativas: Fondaparinux, argatroban",
                "children": []
              }
            ]
          },
          {
            "text": "2ï¸âƒ£ Control de\\NpresiÃ³n intracraneal",
            "children": [
              {
                "text": "âœ”ï¸ Manejo de HIC con acetazolamida, furosemida",
                "children": []
              },
              {
                "text": "âœ”ï¸ Drenaje ventricular en casos severos",
                "children": []
              }
            ]
          },
          {
            "text": "3ï¸âƒ£ TrombÃ³lisis y trombectomÃ­a mecÃ¡nica",
            "children": [
              {
                "text": "âœ”ï¸ Casos severos, deterioro rÃ¡pido, refractarios a anticoagulaciÃ³n",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ PronÃ³stico:",
            "children": [
              {
                "text": "âœ”ï¸ Mortalidad <5% con tratamiento adecuado",
                "children": []
              },
              {
                "text": "âœ”ï¸ RecuperaciÃ³n funcional en mayorÃ­a",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "PRESENTACIÃ“N\\NCLÃNICA DE CVT",
        "children": [
          {
            "text": "â¤ SÃ­ntomas variados â†’ Imitan otros trastornos neurolÃ³gicos",
            "children": []
          },
          {
            "text": "â¤ Dependen de la ubicaciÃ³n del trombo",
            "children": []
          },
          {
            "text": "â¤ AfectaciÃ³n simultÃ¡nea de mÃºltiples senos venosos â†’ PresentaciÃ³n mixta",
            "children": []
          },
          {
            "text": "â¤ DiagnÃ³stico tardÃ­o (mediana: 7 dÃ­as - ISCVT)",
            "children": []
          },
          {
            "text": "â¤ 3.6% de pacientes con CVT en emergencias son mal diagnosticados",
            "children": []
          }
        ]
      },
      {
        "text": "SÃNDROMES CLÃNICOS\\NPRINCIPALES",
        "children": [
          {
            "text": "1ï¸âƒ£ SÃ­ndrome de hipertensiÃ³n\\Nintracraneal (HIC) aislada",
            "children": [
              {
                "text": "ğŸ“Œ SÃ­ntomas",
                "children": [
                  {
                    "text": "âœ”ï¸ Cefalea (90% de pacientes)",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ VÃ³mitos",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Papiledema Â± pÃ©rdida visual",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ ParÃ¡lisis del VI par (diplopÃ­a)",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Subgrupos",
                "children": [
                  {
                    "text": "âœ”ï¸ HIC aislada (sin signos neurolÃ³gicos focales) â†’ 33% de CVT",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Cefalea aislada (sin signos de HIC ni neurolÃ³gicos) â†’ 25% de CVT",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ CaracterÃ­sticas de cefalea\\Npor CVT",
                "children": [
                  {
                    "text": "âœ”ï¸ Empeora con maniobra de Valsalva y decÃºbito",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Inicio subagudo",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ MÃ¡s difusa que unilateral",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Puede simular migraÃ±a o cefalea en trueno",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "2ï¸âƒ£ DÃ©ficit neurolÃ³gico focal\\Ny crisis epilÃ©pticas",
            "children": [
              {
                "text": "ğŸ“Œ SÃ­ntomas\\Nfrecuentes",
                "children": [
                  {
                    "text": "âœ”ï¸ Hemiparesia",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Afasia",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ PÃ©rdida visual",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ CaracterÃ­sticas\\Nclave",
                "children": [
                  {
                    "text": "âœ”ï¸ DÃ©ficits progresivos (â‰  ACV arterial sÃºbito)",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ SÃ­ntomas bilaterales si afecta seno sagital superior",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Crisis epilÃ©pticas",
                "children": [
                  {
                    "text": "âœ”ï¸ 40% de los casos â†’ mÃ¡s frecuente que en ACV arterial",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Generalizadas o focales",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "3ï¸âƒ£ EncefalopatÃ­a subaguda",
            "children": [
              {
                "text": "ğŸ“Œ LocalizaciÃ³n: Sistema venoso profundo",
                "children": []
              },
              {
                "text": "ğŸ“Œ SÃ­ntomas:",
                "children": [
                  {
                    "text": "âœ”ï¸ ConfusiÃ³n",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Letargo",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Deterioro neurolÃ³gico rÃ¡pido â†’ Coma",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Causa: Edema bilateral del tÃ¡lamo y ganglios basales",
                "children": []
              }
            ]
          },
          {
            "text": "4ï¸âƒ£ SÃ­ndrome del seno cavernoso",
            "children": [
              {
                "text": "ğŸ“Œ MÃºltiples neuropatÃ­as craneales",
                "children": []
              },
              {
                "text": "ğŸ“Œ Compromiso de pares III, IV, V1-V2 y VI",
                "children": []
              },
              {
                "text": "ğŸ“Œ OftalmoplejÃ­a + proptosis + dolor ocular",
                "children": []
              },
              {
                "text": "ğŸ“Œ IMPORTANTE:",
                "children": [
                  {
                    "text": "âœ”ï¸ 10% de pacientes con CVT tienen trombosis del sistema venoso profundo",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Trombosis de venas corticales aisladas â†’ Muy rara (subdiagnosticada)",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "HALLAZGOS\\NRADIOLÃ“GICOS EN CVT",
        "children": [
          {
            "text": "â¤ DiagnÃ³stico basado en imagenologÃ­a â†’ Alta sospecha clÃ­nica",
            "children": []
          },
          {
            "text": "â¤ TAC inicial en emergencia â†’ Limitaciones en sensibilidad",
            "children": []
          },
          {
            "text": "â¤ RM + venografÃ­a son clave para el diagnÃ³stico definitivo",
            "children": []
          },
          {
            "text": "TOMOGRAFÃA\\NCOMPUTARIZADA (TAC)",
            "children": [
              {
                "text": "ğŸ“Œ Hallazgos claves en CVT",
                "children": [
                  {
                    "text": "âœ”ï¸ Signo del trombo denso (â€œDense clot signâ€)",
                    "children": [
                      {
                        "text": "â¡ï¸ Trombo hiperdenso en seno venoso",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "âœ”ï¸ Signo del cordÃ³n (â€œCord signâ€)",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Signo del delta vacÃ­o (â€œEmpty delta signâ€)",
                    "children": [
                      {
                        "text": "â¡ï¸ Defecto de llenado en senos venosos durales tras contraste",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "âœ”ï¸ Hemorragia intraparenquimatosa (~30% de CVT)",
                    "children": [
                      {
                        "text": "â¡ï¸ MÃºltiples hematomas intraparenquimatosos",
                        "children": []
                      },
                      {
                        "text": "â¡ï¸ Infartos mal definidos, no arteriales",
                        "children": []
                      },
                      {
                        "text": "â¡ï¸ AfectaciÃ³n bilateral del tÃ¡lamo o ganglios basales",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "âœ”ï¸ HipertensiÃ³n intracraneal",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Limitaciones de TAC",
                "children": [
                  {
                    "text": "âŒ DifÃ­cil descartar CVT solo con TAC simple",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "CASO CLÃNICO\\N(Caso 7-1)",
        "children": [
          {
            "text": "ğŸ‘¨ Paciente: Hombre 60 aÃ±os, derecho",
            "children": []
          },
          {
            "text": "ğŸ†˜ SÃ­ntomas: Afasia mixta",
            "children": []
          },
          {
            "text": "ğŸ“‰ Hallazgos en imagen:",
            "children": [
              {
                "text": "âœ”ï¸ TAC simple: Hemorragia temporal izquierda + extensiÃ³n subaracnoidea",
                "children": []
              },
              {
                "text": "âœ”ï¸ TAC venografÃ­a: Trombosis en seno transverso, sigmoideo, vena yugular interna y vena de LabbÃ©",
                "children": []
              },
              {
                "text": "âœ”ï¸ RM T1: ConfirmaciÃ³n de trombosis en vena de LabbÃ©",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ DiagnÃ³stico final: CVT con HIC e infarto venoso",
            "children": []
          },
          {
            "text": "ğŸ“Œ Comentario:",
            "children": [
              {
                "text": "âœ”ï¸ Dificultades en diagnÃ³stico inicial de CVT",
                "children": []
              },
              {
                "text": "âœ”ï¸ Importancia de imagen avanzada",
                "children": []
              },
              {
                "text": "âœ”ï¸ AnticoagulaciÃ³n + antiepilÃ©pticos (solo si crisis epilÃ©ptica previa)",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "IMAGEN\\NAVANZADA EN\\NCVT",
        "children": [
          {
            "text": "1ï¸âƒ£ TAC VenografÃ­a",
            "children": [
              {
                "text": "ğŸ“Œ TÃ©cnica:",
                "children": [
                  {
                    "text": "âœ”ï¸ TAC helicoidal con bolo de contraste",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Ventajas:",
                "children": [
                  {
                    "text": "âœ”ï¸ Buena sensibilidad",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Permite visualizar trombosis en senos venosos",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Limitaciones:",
                "children": [
                  {
                    "text": "âŒ Especificidad baja",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "2ï¸âƒ£ Resonancia MagnÃ©tica (RM)\\Ncon VenografÃ­a (MRV)",
            "children": [
              {
                "text": "ğŸ“Œ TÃ©cnica:",
                "children": [
                  {
                    "text": "âœ”ï¸ MRV con contraste",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Secuencias T1, T2, SWI*",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Hallazgos\\NClaves en RM:",
                "children": [
                  {
                    "text": "âœ”ï¸ VisualizaciÃ³n del trombo en T1",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ EvoluciÃ³n del trombo en\\NRM segÃºn tiempo:",
                    "children": [
                      {
                        "text": "â¡ï¸ DÃ­a 1-5: Isointenso en T1, Hipointenso en T2*",
                        "children": []
                      },
                      {
                        "text": "â¡ï¸ DÃ­a 5-15: Hiperintenso en T1 y T2*",
                        "children": []
                      },
                      {
                        "text": "â¡ï¸ DÃ­a >15: Hipointenso homogÃ©neo en todas las secuencias",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "âœ”ï¸ Trombosis de venas corticales â†’ DifÃ­cil sin SWI o T2*",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Ventajas de MRV\\Ncon contraste:",
                "children": [
                  {
                    "text": "âœ”ï¸ Mejor sensibilidad/especificidad vs. MRV TOF (Time-of-Flight)",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ No tiene artefactos de flujo",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Alternativa\\Nexperimental:",
                "children": [
                  {
                    "text": "âœ”ï¸ Imagen de trombo â€œBlack-blood thrombus imagingâ€ (T1 sin contraste)",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Alta sensibilidad y especificidad",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "3ï¸âƒ£ Hallazgos Especiales en RM",
            "children": [
              {
                "text": "ğŸ“Œ Signo del â€œBrush Signâ€ (Figura 7-4)",
                "children": [
                  {
                    "text": "âœ”ï¸ Hipointensidad en venas subependimarias y medulares profundas (T2)*",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Asociado a trombosis del sistema venoso profundo",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Marcador de CVT severa",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "ğŸ“Œ IMPORTANTE:",
            "children": [
              {
                "text": "âœ”ï¸ DiagnÃ³stico requiere IMAGEN AVANZADA",
                "children": []
              },
              {
                "text": "âœ”ï¸ RMV con contraste y TAC venografÃ­a son los estudios clave",
                "children": []
              },
              {
                "text": "âœ”ï¸ TAC simple tiene sensibilidad limitada",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "TRATAMIENTO DE CVT",
        "children": [
          {
            "text": "â¤ Opciones:",
            "children": [
              {
                "text": "âœ”ï¸ MÃ©dico (AnticoagulaciÃ³n)",
                "children": []
              },
              {
                "text": "âœ”ï¸ Endovascular (TrombectomÃ­a, trombÃ³lisis)",
                "children": []
              },
              {
                "text": "âœ”ï¸ QuirÃºrgico (CraniectomÃ­a descompresiva, evacuaciÃ³n de hematomas)",
                "children": []
              }
            ]
          },
          {
            "text": "1ï¸âƒ£ ANTICOAGULACIÃ“N\\NAGUDA",
            "children": [
              {
                "text": "ğŸ“Œ Tratamiento de primera lÃ­nea, incluso con hemorragia",
                "children": []
              },
              {
                "text": "ğŸ“Œ AHA/ASA y ESO\\Nrecomiendan:",
                "children": [
                  {
                    "text": "âœ”ï¸ Heparina no fraccionada (HNF) o heparina de bajo peso molecular (HBPM)",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ HBPM preferida sobre HNF (Menos hemorragia y mejor resultado funcional)",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Objetivos de\\NanticoagulaciÃ³n:",
                "children": [
                  {
                    "text": "âœ”ï¸ RecanalizaciÃ³n del trombo",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Mejora de perfusiÃ³n regional",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ PrevenciÃ³n de tromboembolismo venoso (TEV)",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Evidencia:",
                "children": [
                  {
                    "text": "âœ”ï¸ 85% de recanalizaciÃ³n tras anticoagulaciÃ³n",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Riesgo de embolismo pulmonar â¬†ï¸ en CVT no anticoagulada",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "2ï¸âƒ£ DURACIÃ“N DE LA\\NANTICOAGULACIÃ“N",
            "children": [
              {
                "text": "ğŸ“Œ No hay ensayos controlados aleatorizados â†’ Basado en TEV",
                "children": []
              },
              {
                "text": "ğŸ“Œ AHA/ASA:",
                "children": [
                  {
                    "text": "âœ”ï¸ CVT provocada (factor de riesgo transitorio): 3-6 meses",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ CVT no provocada: 6-12 meses",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ CVT recurrente o trombofilia grave: AnticoagulaciÃ³n indefinida",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Ensayo EXCOA-CVT en curso para definir duraciÃ³n Ã³ptima",
                "children": []
              }
            ]
          },
          {
            "text": "3ï¸âƒ£ ANTICOAGULANTES\\NORALES DIRECTOS (DOACs)",
            "children": [
              {
                "text": "ğŸ“Œ Alternativa a warfarina tras fase aguda",
                "children": []
              },
              {
                "text": "ğŸ“Œ Ventajas de DOACs:",
                "children": [
                  {
                    "text": "âœ”ï¸ Menos sangrado mayor",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ FarmacocinÃ©tica predecible, sin monitoreo",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Eficacia similar a antagonistas de vitamina K (AVK)",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Evidencia:",
                "children": [
                  {
                    "text": "âœ”ï¸ RESPECT-CVT: DabigatrÃ¡n similar a warfarina en prevenciÃ³n de TEV",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ EINSTEIN-Jr: RivaroxabÃ¡n en niÃ±os con CVT â†’ Seguridad similar a AVK",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ ACTION-CVT: Similar eficacia y menor sangrado mayor que AVK",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Contraindicaciones:",
                "children": [
                  {
                    "text": "âŒ SÃ­ndrome antifosfolÃ­pido (SAPL) â†’ Aumento de eventos arteriales con DOACs",
                    "children": []
                  },
                  {
                    "text": "âŒ Embarazo â†’ Preferir HBPM",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "4ï¸âƒ£ TERAPIA ENDOVASCULAR",
            "children": [
              {
                "text": "ğŸ“Œ Indicada solo en casos graves o refractarios a anticoagulaciÃ³n",
                "children": []
              },
              {
                "text": "ğŸ“Œ Opciones:",
                "children": [
                  {
                    "text": "âœ”ï¸ TrombectomÃ­a mecÃ¡nica",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ TrombÃ³lisis local",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Ensayo TO-ACT:",
                "children": [
                  {
                    "text": "âŒ No mostrÃ³ beneficio sobre anticoagulaciÃ³n sola",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "5ï¸âƒ£ TRATAMIENTO DE\\NVITT-ASOCIADO A CVT",
            "children": [
              {
                "text": "ğŸ“Œ Vacuna COVID-19 (Adenovirus) â†’ Trombosis con trombocitopenia (VITT)",
                "children": []
              },
              {
                "text": "ğŸ“Œ Manejo:",
                "children": [
                  {
                    "text": "âœ”ï¸ AnticoagulaciÃ³n sin heparina (Fondaparinux, argatrobÃ¡n)",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Inmunoglobulina IV (1 g/kg/dÃ­a x 2 dÃ­as)",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ PlasmafÃ©resis si refractario",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Evitar:",
                "children": [
                  {
                    "text": "âŒ Heparina",
                    "children": []
                  },
                  {
                    "text": "âŒ TransfusiÃ³n de plaquetas (riesgo de trombosis)",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "6ï¸âƒ£ CIRUGÃA DESCOMPRESIVA",
            "children": [
              {
                "text": "ğŸ“Œ IndicaciÃ³n:",
                "children": [
                  {
                    "text": "âœ”ï¸ Hernia cerebral por edema o hemorragia venosa",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Procedimientos:",
                "children": [
                  {
                    "text": "âœ”ï¸ CraniectomÃ­a descompresiva",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ EvacuaciÃ³n de hematoma",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Resultados:",
                "children": [
                  {
                    "text": "âœ”ï¸ Mortalidad ~4% en CVT severa",
                    "children": []
                  },
                  {
                    "text": "âœ”ï¸ Supervivencia con buena recuperaciÃ³n en 80%",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "7ï¸âƒ£ PROFILAXIS DE TEV EN CVT",
            "children": [
              {
                "text": "ğŸ“Œ Indicada en embarazo tras CVT previa",
                "children": []
              },
              {
                "text": "ğŸ“Œ AHA/ASA y ESO recomiendan:",
                "children": [
                  {
                    "text": "âœ”ï¸ HBPM durante toda la gestaciÃ³n",
                    "children": []
                  }
                ]
              },
              {
                "text": "ğŸ“Œ Evidencia:",
                "children": [
                  {
                    "text": "âœ”ï¸ â¬‡ï¸ Recurrencia de CVT sin aumento de hemorragia",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "ğŸ“Œ IMPORTANTE:",
            "children": [
              {
                "text": "âœ”ï¸ AnticoagulaciÃ³n es el tratamiento base en CVT",
                "children": []
              },
              {
                "text": "âœ”ï¸ DOACs son seguros y eficaces, pero no en SAPL ni embarazo",
                "children": []
              },
              {
                "text": "âœ”ï¸ TrombectomÃ­a reservada para casos severos refractarios",
                "children": []
              },
              {
                "text": "âœ”ï¸ CraniectomÃ­a descompresiva salva vidas en herniaciÃ³n cerebral",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "PRONÃ“STICO Y RESULTADOS\\NCLÃNICOS EN CVT",
        "children": [
          {
            "text": "ğŸ“Œ Mortalidad baja",
            "children": [
              {
                "text": "âœ”ï¸ Intrahospitalaria: 1-4%",
                "children": []
              },
              {
                "text": "âœ”ï¸ A largo plazo: 8-10%",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ Mortalidad en descenso",
            "children": [
              {
                "text": "âœ”ï¸ RelaciÃ³n inversa entre mortalidad y aÃ±o de diagnÃ³stico",
                "children": []
              },
              {
                "text": "âœ”ï¸ Menos dÃ©ficits focales y coma al diagnÃ³stico",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ Factores:",
            "children": [
              {
                "text": "âœ”ï¸ Mejor tratamiento",
                "children": []
              },
              {
                "text": "âœ”ï¸ DiagnÃ³stico temprano",
                "children": []
              },
              {
                "text": "âœ”ï¸ IdentificaciÃ³n de casos menos graves",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ Resultados funcionales",
            "children": [
              {
                "text": "âœ”ï¸ 82% con mRS 0-1 a los 6 meses",
                "children": []
              },
              {
                "text": "âœ”ï¸ Pero 68% reporta sÃ­ntomas residuales",
                "children": []
              },
              {
                "text": "âœ”ï¸ SÃ­ntomas comunes:",
                "children": [
                  {
                    "text": "â¡ï¸ DÃ©ficits neuropsicolÃ³gicos",
                    "children": []
                  },
                  {
                    "text": "â¡ï¸ Cefalea persistente",
                    "children": []
                  },
                  {
                    "text": "â¡ï¸ Crisis epilÃ©pticas",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "ğŸ“Œ Impacto en calidad de vida",
            "children": [
              {
                "text": "âœ”ï¸ Secuelas pueden afectar empleabilidad",
                "children": []
              },
              {
                "text": "âœ”ï¸ Se necesita mÃ¡s investigaciÃ³n en rehabilitaciÃ³n post-CVT",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "CONCLUSIÃ“N",
        "children": [
          {
            "text": "ğŸ“Œ Cambios en la\\NepidemiologÃ­a de CVT",
            "children": [
              {
                "text": "âœ”ï¸ Mayor detecciÃ³n en adultos mayores",
                "children": []
              },
              {
                "text": "âœ”ï¸ Mayor incidencia reportada",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ DiagnÃ³stico",
            "children": [
              {
                "text": "âœ”ï¸ PresentaciÃ³n variable y sutil â†’ DifÃ­cil diferenciar de otras enfermedades cerebrovasculares",
                "children": []
              },
              {
                "text": "âœ”ï¸ Neuroimagen avanzada (RM con contraste) es clave",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ Tratamiento",
            "children": [
              {
                "text": "âœ”ï¸ DOACs seguros y eficaces â†’ Uso creciente en prÃ¡ctica clÃ­nica",
                "children": []
              },
              {
                "text": "âœ”ï¸ VITT postvacuna COVID-19 es raro (<5/millÃ³n dosis), casi nulo en vacunas mRNA",
                "children": []
              },
              {
                "text": "âœ”ï¸ Beneficio de la vacunaciÃ³n supera ampliamente el riesgo de VITT",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "PUNTOS CLAVE",
        "children": [
          {
            "text": "ğŸ“Œ 1ï¸âƒ£ CaracterÃ­sticas generales",
            "children": [
              {
                "text": "âœ”ï¸ Amplio espectro clÃ­nico â†’ No apoplÃ©ctico",
                "children": []
              },
              {
                "text": "âœ”ï¸ Afecta jÃ³venes, predominio femenino",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ 2ï¸âƒ£ Incidencia",
            "children": [
              {
                "text": "âœ”ï¸ 1.32 - 2/100,000 adultos/aÃ±o",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ 3ï¸âƒ£ Factores predisponentes vs. precipitantes",
            "children": [
              {
                "text": "âœ”ï¸ Predisponentes: SAPL, trombofilias, cÃ¡ncer",
                "children": []
              },
              {
                "text": "âœ”ï¸ Precipitantes: ACOs, infecciones, embarazo/puerperio",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ 4ï¸âƒ£ RelaciÃ³n con COVID-19",
            "children": [
              {
                "text": "âœ”ï¸ CVT asociada a infecciÃ³n por COVID-19 (Mecanismo incierto)",
                "children": []
              },
              {
                "text": "âœ”ï¸ VITT postvacuna adenoviral â†’ Algoritmo diagnÃ³stico/tratamiento",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ 5ï¸âƒ£ SÃ­ndromes clÃ­nicos",
            "children": [
              {
                "text": "âœ”ï¸ 1. HipertensiÃ³n intracraneal aislada (cefalea)",
                "children": []
              },
              {
                "text": "âœ”ï¸ 2. DÃ©ficits neurolÃ³gicos focales (progresivos, â‰  ACV arterial)",
                "children": []
              },
              {
                "text": "âœ”ï¸ 3. EncefalopatÃ­a subaguda (afectaciÃ³n venosa profunda)",
                "children": []
              },
              {
                "text": "âœ”ï¸ 4. SÃ­ndrome del seno cavernoso (pares craneales mÃºltiples)",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ 6ï¸âƒ£ DiagnÃ³stico",
            "children": [
              {
                "text": "âœ”ï¸ RM con contraste > MRV sin contraste",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ 7ï¸âƒ£ Tratamiento",
            "children": [
              {
                "text": "âœ”ï¸ HBPM o HNF â†’ Luego AVK o DOACs",
                "children": []
              },
              {
                "text": "âœ”ï¸ DOACs con buen perfil de seguridad (excepto en SAPL/embarazo)",
                "children": []
              },
              {
                "text": "âœ”ï¸ TrombectomÃ­a solo en casos graves refractarios",
                "children": []
              },
              {
                "text": "âœ”ï¸ CraniectomÃ­a descompresiva recomendada en herniaciÃ³n",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ 8ï¸âƒ£ PronÃ³stico",
            "children": [
              {
                "text": "âœ”ï¸ Mortalidad baja (1-4% intrahospitalaria, 8-10% a largo plazo)",
                "children": []
              },
              {
                "text": "âœ”ï¸ Secuelas persistentes en 68% (cefalea, dÃ©ficits neuropsicolÃ³gicos, crisis epilÃ©pticas)",
                "children": []
              }
            ]
          },
          {
            "text": "ğŸ“Œ IMPORTANTE:",
            "children": [
              {
                "text": "âœ”ï¸ CVT tiene pronÃ³stico favorable con diagnÃ³stico y tratamiento oportuno",
                "children": []
              },
              {
                "text": "âœ”ï¸ DOACs han cambiado el manejo de CVT",
                "children": []
              },
              {
                "text": "âœ”ï¸ Importancia de sospecha clÃ­nica y uso de neuroimagen avanzada",
                "children": []
              }
            ]
          }
        ]
      }
    ]
  },
  "related_maps": [
    {
      "id": "map_1633",
      "title": "ACV: ESCALAS DE UTILIDAD CLÃNICA"
    },
    {
      "id": "map_1689",
      "title": "SPRINTT (2021)\\NSarcopenia and Physical\\NFragility in Older People:\\NMulti-component Treatment\\N\\nâ­ Ejercicio + nutriciÃ³n reduce\\ndiscapacidad en fragilidad fÃ­sica\\ncon sarcopenia"
    },
    {
      "id": "map_1785",
      "title": "ELDERCARE-AF (2020)\\NEdoxaban Low-Dose for\\NEldeRly patiEnts with\\NAtrial Fibrillation\\N\\nâ­ Edoxaban 15mg reduce ACV 66%\\nvs placebo en muy ancianos\\nno candidatos a ACO estÃ¡ndar"
    },
    {
      "id": "map_1427",
      "title": "Inmunoglobulina Intravenosa (IVIg) como Terapia de Rescate en Anemia HemolÃ­tica Autoinmune (AHAI) Grave del Adulto: Estudio Observacional MulticÃ©ntrico FrancÃ©s **(Publicado 2024)**"
    },
    {
      "id": "map_1640",
      "title": "Aciclovir (ACV) versus Valaciclovir (VACV)"
    }
  ],
  "source_file": "Continuum. DiagnoÌstico y tratamiento de la trombosis venosa cerebral-2025.smmx",
  "created": "2026-02-07T15:42:58.610001"
}